All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
TABLE TEST
During the European Society of Hematology (ESH) 2nd How I manage: CAR-T therapies and bispecific antibodies for my patients 2023 Congress, the Lymphoma Hub spoke to Ulrich Jӓger, Medical University of Vienna, Vienna, AT. We asked, What are the key updates from ESH 2nd How I manage: CAR-T therapies and bispecific antibodies?
| Treatment | Trial | Primary ACR response endpoint | ||||
| Interleukin inhibitors | ||||||
| Secukinumab |
| |||||
| Secukinumab1 | FUTURE 4 (NCT01989468)6 | ACR20 at Week 24 (n = 132) Secukinumab 300 mg autoinjector: 40.9% (p < 0.01) Secukinumab 150 mg autoinjector: 34.1% (p < 0.05) Placebo: 9.1% | ||||
| Secukinumab | FUTURE 2 (NCT01752634)5 | Secukinumab 150 mg autoinjector: 34.1% (p < 0.05) |
| Secukinumab | FUTURE 2 (NCT01752634)5 | Secukinumab 150 mg autoinjector: 34.1% (p < 0.05) |
Solution
| Treatment | Trial | Primary ACR response endpoint |
| Interleukin inhibitors | ||
| Secukinumab.. | FUTURE 2 (NCT01752634)5 | ACR20 at Week 24 Secukinumab 300 mg SC: 45% (n = 33; p = 0.0077) Secukinumab 150 mg SC: 30% (n = 37; p = 0.1216) Placebo: 14% (n = 35) |
| FUTURE 3 (NCT01989468)6 | ACR20 at Week 24 (n = 132) Secukinumab 300 mg autoinjector: 40.9% (p < 0.01) Secukinumab 150 mg autoinjector: 34.1% (p < 0.05) Placebo: 9.1% | |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content